The DAK-Gesundheit is seeking to establish a non-exclusive discount agreement for the drug Olopatadine (ATC S01GX09) under Section 130a, Paragraph 8 of the German Social Code (SGB V). This agreement will be effective from September 1, 2024, to August 31, 2026. The process will involve formal procure
Contract awarded. Originally published 1 years ago.
Only 2 prior awards here — too little to read.
In healthcare medical, DAK HEALTH has awarded 2 contracts to 2 suppliers.
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This contract opportunity involves the collection of used paper and the destruction of documents and data carriers across Germany. Suppliers are invited to provide services that include the secure destruction of paper, cardboard, and other materials. Detailed specifications of the required services
DAK Health is seeking external support for the development of innovative IT solutions in response to the ongoing digital transformation in the German healthcare sector. This need arises from new legal requirements and the challenges posed by a volatile political environment and a shortage of skilled
This contract involves a non-exclusive discount agreement for the pharmaceutical substances Adapalene and Benzoyl Peroxide, classified under ATC code D10AD23. The agreement is established under Section 130a, Paragraph 8 of the German Social Code (SGB V), allowing health insurance funds and pharmaceu
DAK Health is seeking external support for the development of innovative IT solutions in response to the ongoing digitalization of the German healthcare system and related legal requirements. Due to the volatile political environment and the structural shortage of skilled IT professionals, DAK Healt
Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.
Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.
UKHSA seeks supplier information for Doxycycline 10-pack supply through a preliminary market engagement exercise under the Procurement Act 2023.
Suppliers are invited to complete a preliminary market engagement questionnaire about patient diagnostic and monitoring electrodes by 21st September 2026 through eTendersNI.
